Estimation of direct and indirect cost of diabetes in Morocco

Wiam Boutayeb, Mohamed E. N. Lamlili, Abdesslam Boutayeb, Saber Boutayeb

Department of Mathematics, Faculty of Sciences, University Mohamed 1st, Oujda, Morocco.
Department of Medical Oncology, National Institute of Oncology, Rabat, Morocco.
Laboratory of Stochastic and Determinist Modeling, Research Unit Associated to CNRST, Faculty of Sciences, University Mo- hamed 1st, Oujda, Morocco.

DOI: 10.4236/jbise.2013.67090                

Abstract

Due to its chronic nature with severe complications, diabetes needs costly prolonged treatment and care. The high economic burden of diabetes is particularly threatening low and middle income countries. World-wide, studies have shown that the cost of diabetes per person is much higher than the per capita health expenditure. This study is the first to estimate the direct and indirect cost of diabetes in Morocco. The direct cost of diabetes was computed by assuming three scenarios of prices (low, medium and high) due to different prices of insulin, oral drugs and other items used in diabetes treatment and care. Indirect costs of diabetes were estimated by the lifetime forgone earnings caused by premature death and disability due to diabetes. The direct cost of diabetes in Morocco was estimated to be between US $0.47 and US $1.5 billion whereas the indirect cost was estimated to be around US $2 billion accounting for 57% of the total cost of diabetes under the high cost scenario, 69% under the medium scenario and 81% under the low cost scenario. The average per capita indirect cost was estimated to be US $1113, relatively higher than the direct cost of diabetes which was seen to vary from US$ 259 to US $830. The results yielded by this study were compared to those obtained by similar studies in different regions and countries of the world. As a conclusion, the findings of this study indicate a high economic burden of diabetes and stress the importance that Moroccan health decision makers should give to sensitisation, early diagnosis and treatment of diabetes especially with the crucial growing trend of diabetes prevalence.

Keywords

Diabetes; Direct Cost; Indirect Cost; Prevalence; Productive Life Years; Disability

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Boutayeb, A. and Boutayeb, S. (2005) The burden of NCDs in developing countries. International Journal for Equity in Health, 4, 2. doi:10.1186/1475-9276-4-2
[2]	World Health Organisation (2010) The cost of diabetes. http://www.who.int/mediacentre/factsheets/ fs236/en/
[3]	Al-Maskari, F., El-Sadig, M. and Nagelkerke, N. (2010) Assessment of the direct medical costs of diabetes mellitus and its complications in the United Arab Emirates. BMC Public Health, 10, 679. http://www.biomedcentral.com/174-2458/10/679 doi:10.1186/1471-2458-10-679
[4]	Barcelo, A., Aedo, C., Rajpathak, S. and Robles, S. (2003) The cost of diabetes in Latin America and the Caribbean. Bulletin of the World Health Organization, 81, 19-27.
[5]	Kirigia, J.M., Sambo, H.B., Sambo, G. and Barry, S.P. (2009) Economic burden of diabetes in the WHO African region. BMC International Health and Human Rights, 9, 6. http://www.biomedcentral.com/ 1472-698X/9/8 doi:10.1186/1472-698X-9-6
[6]	Kim, T.H., Chun, K.H. and Kim, H.J. (2012) Direct medical costs for patients with type 2 diabetes and related complications: A prospective cohort study based on the Korean national diabetes program. Journal of Korean Medical Sciences, 27, 876-882. doi:10.3346/jkms.2012.27.8.876
[7]	American Diabetic Association (2008) Economic costs of diabetes in the US in 2007. Diabetes Care, 31, 596-615.
[8]	Canadian Diabetes Association (2010) An economic tsunami: The cost of diabetes in Canada.
[9]	Diabetes UK (2010) Diabetes in the UK 2010: Key statistics on diabetes. http://www.diabetes.org.uk /Documents/Reports/Diabetes_in_the_UK_2010.pdf
[10]	International Diabetes Federation (2011) IDF Diabetes Atlas. 5th Edition, IDF, Bressels.
[11]	World Health Organisation (2013) Morocco health profile. http://www.who.int/gho/countries/mar.pdf
[12]	Moroccan Ministry of Health (2010) Santé vision 2020. http://www.sante.gov.ma/Vision/Sante-Vision%202020.pdf
[13]	Tazi, M.A., Abir-Khalil, S., Chaouki, N., Cherqaoui, S., Lahmouz, F. and Srairi, J.E. (2000) Prevalence of the main cardiovascular risk factors in Morocco: Results of a National Survey 2000. Journal of Hypertension, 21, 897 903. doi:10.1097/00004872-200305000-00013
[14]	Ramdani, N., Vanderpas, J., Boutayeb, A., Meziane, A., Hassani, B., Zoheir, J., Legssyer, A., Aziz, M., Mekhfi, H., Bnouham, M. and Ziyyat, A. (2012) Diabetes and obesity in the eastern Morocco. Mediterranean Journal of Nutrition and Metabolism, 5, 149-155. doi:10.1007/s12349-011-0087-2
[15]	Boutayeb, A., Lamlili, M., Boutayeb, W., Maamri, A., Ziyyat, A. and Ramdani, N. (2012) The rise of diabetes prevalence in the Arab region. Open Journal of Epidemiology, 2, 55-60.
[16]	National Agency of Health Insurance (2013) Agencenationale assurance maladie: ANAM. http://www.assurancemaladie.ma/anam.php?id_espace=6
[17]	Bjork, S. (2001) The cost of diabetes and diabetes care. Diabetes Research and Clinical Practice, 54, S13-S18. doi:10.1016/S0168-8227(01)00304-7
[18]	Murray, C. and Lopez, A.D. (1996) Global health statistics: A compendium of incidence, prevalence and mortality estimates for over 200 conditions. World Health Organization, Geneva.
[19]	Khowaja, L.A., Khuwaja, A.K. and Cosgrove, P. (2007) Cost of diabetes care in out-patient clinics of Karachi, Pakistan. BMC Health Services Research, 7, 189. doi:10.1186/1472-6963-7-189
[20]	Boutayeb, A. (2012) Reader’s comments: Discussion of estimation parameters. BMC International Health and Human Rights, 9, 6. http://www.biomedcentral.com/1472-698X/9/6/comments
[21]	Boutayeb, A. (2006) The double burden of communicable and non-communicable diseases in developing countries. Transactions of the Royal Society of Tropical Medicine and Hygiene, 100, 191-199. doi:10.1016/j.trstmh.2005.07.021
[22]	UKPDS (UK Prospective Diabetes Study) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 352, 837-853. doi:10.1016/S0140-6736(98)07019-6
[23]	Venkat, K.M., Zhang, N.P., Kanaya, A.M., Williams, D.E., Engelgau, M.M., Imperatore, G. and Ramachandran, A. (2006) Diabetes: The pandemic and potential solutions. In: Jamison, D.T., et al., Eds., Disease Control Priorities in Developing Countries, World Bank, Washington DC, 2006.